WilmerHale represented Nodexus Inc., an emerging leader in the development of automated live cell characterization and isolation technologies, in its $30M Series A financing that will allow the company to expand the manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet an increasing demand.
The NX One system provides affordable walk-up usable automated single-cell sorting and dispensing to enable deployment into any lab working on bioprocessing, cancer biology research, gene editing and other expanding applications. The Series A funding will allow Nodexus to substantially grow its team and support its mission to “democratize biological tools.”
The WilmerHale team representing Nodexus was led by Joe Wyatt and included Molly Holsinger, Elise Brumbach and Sharon Baek.